A double-blind, randomized, placebo-controlled crossover trial of the α2C-adrenoceptor antagonist ORM-12741 for prevention of cold-induced vasospasm in patients with systemic sclerosis.

Author: Herrick AL, Murray AK, Ruck A, et al
Date Published: May-2014
Source: Rheumatology Oxford, England

Skin involvement with dermal fibrosis is a hallmark of systemic sclerosis and keratinocytes may be critical regulators of fibroblast function through secretion of chemo-attracting agents, as well as growth factors and cytokines influencing phenotype and proliferation rate of fibroblasts, and epithelial-fibroblast interactions have an important role in fibrosis in general. We have characterised SSc epidermis and asked whether SSc injured epidermal cells are releasing factors capable of promoting fibrosis.